Atheroma Volume by Intravascular Ultrasound as a Surrogate for Clinical End Points

Journal of the American College of Cardiology

Volumn 53, Issue 13, 2009, Pages 1116-1118

  Tobis, Jonathan M ^a   Perlowski, Alice ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

atherosclerosis; coronary artery disease; hypertension; intravascular ultrasound; LDL cholesterol

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN;

ATHEROMA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; EDITORIAL; HUMAN; HYPERTENSION; INTRAVASCULAR ULTRASOUND; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; HUMANS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 62549115716     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.11.049     Document Type: Editorial

References (22)

1. Cannon C.P., Steinberg B.A., Murphy S.A., Mega J.L., and Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48 (2006) 438-445
2. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., and Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
4. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
5. Chhatriwalla A.K., Nicholls S.J., Wang T.H., et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol 53 (2009) 1110-1115
6. Teo K.K., Burton J.R., Buller C.E., et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 102 (2000) 1748-1754
7. Howard B.V., Roman M.J., Devereux R.B., et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 299 (2008) 1678-1689
8. Kato M., Sada T., Mizuno M., Kitayama K., Inaba T., and Koike H. Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits. J Cardiovasc Pharmacol 46 (2005) 556-562
9. Trion A., de Maat M., Jukema W., et al. Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3- Leiden/hCRP transgenic mice. J Cardiovasc Pharmacol 47 (2006) 89-95
10. Ceriello A., Assaloni R., Da Ros R., et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 111 (2005) 2518-2524
11. Koh K.K., Quon M.J., Han S.H., et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 45 (2005) 1088-1093
12. Koh K.K., Quon M.J., Han S.H., Ahn J.Y., Lee Y., and Shin E.K. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. Atherosclerosis 194 (2007) 230-237
13. Lloyd-Jones D.M., Evans J.C., and Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 294 (2005) 466-472
14. Nissen S.E. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis With Aggressive Lipid Lowering (REVERSAL) trial. Am J Med 118 (2005) 22S-27S
15. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
16. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
17. Nissen S.E., Tuzcu E.M., Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292 (2004) 2217-2225
18. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
19. Nissen S.E., Nicholls S.J., Wolski K., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease. JAMA 299 (2008) 1547-1560
20. Ricciardi M.J., Meyers S., Choi K., Pang J.L., Goodreau L., and Davidson C.J. Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events. Am Heart J 146 (2003) 507-512
21. Von Birgelen C., Hartmann M., Mintz G.S., et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 110 (2004) 1579-1585
22. Kobashigawa J.A., Tobis J.M., Starling R.C., et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 45 (2005) 1532-1537